Dominique Bonnet

He discusses MYB activity drives emergent enhancer activation and enhancer promoter interactions in acute lymphoblastic leukemia with Dr. Thomas Milne.

He also talks with Dr. Dominique Bonnet about her article entitled, Remodeling of the Bone Marrow Vasculature Induced by Venetoclax and Azacitidine Damage.

Hello, everybody.

My name is James Griffin.

This is clearly a key factor in ALL and AML, as you point out.

We're going to go on to the second paper, which is entitled Remodeling of the Bone Marrow Vasculature Induced by Venetoclax and Azacitidine Damage.

And this is going to be discussed by Dr. Dominique Bonnet from the Hematopoietic Stem Cell Laboratory at the Francis Crick Institute in London.

Dr. Bonnet.